{
}
BIO Protocol (BIO) has launched on Binance Launchpool, allowing users to farm BIO coins by staking BNB or FDUSD starting December 24. Trading for BIO will commence on January 3, 2025, with a total supply of 3.32 billion tokens, of which 1.29 billion will be in circulation at launch.The protocol focuses on decentralized scientific research through BioDAOs, which fund projects in areas like longevity and brain health. The token allocation includes 56% for the community, with additional distributions for investors, core contributors, and ecosystem rewards.
DelveInsight's report on Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) forecasts significant market growth by 2034, driven by rising prevalence and awareness. Key players include Glenmark Pharma and AbbVie, with therapies like Zevtera and Dalbavancin leading the charge. The report highlights a higher incidence in men and notes nearly 870,000 hospital admissions in the U.S. due to ABSSSI in 2004.
The global Neostigmine Methylsulfate Injection Market, valued at $156.54 million in 2022, is projected to reach $228.43 million by 2031, growing at a CAGR of 4.4%. The rise in chronic conditions like myasthenia gravis and increased surgical procedures are driving market expansion, particularly in North America and emerging markets. Key players include Pfizer, Fresenius Kabi, and Hikma Pharmaceuticals, with ongoing developments in combination therapies enhancing treatment options.
As 2024 closes with the S&P 500 achieving a 25% return, investors are advised to consider defensive strategies amid potential market volatility. AbbVie, with a strong dividend yield and promising drug sales growth, and Pfizer, offering a high yield and new growth drivers, are highlighted as solid healthcare sector investments for uncertain times. Both companies are well-positioned for continued success as they enter 2025.
Wall Street is experiencing one of its priciest stock markets in history, with the S&P 500's Shiller P/E ratio nearing 39, significantly above the historical average of 17.19. This elevated valuation raises concerns about potential volatility and declines in 2025, prompting a strategy of holding 15% to 30% of portfolios in cash to capitalize on future buying opportunities. Historical trends indicate that when the Shiller P/E exceeds 30, significant market corrections often follow.
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $31. The decision to terminate the lung cancer study with Sasanlimab is attributed to strategic reasons, though high dropout rates raise concerns, particularly regarding the ongoing phase III bladder cancer study.
Pfizer Inc., the leading pharmaceutical group, has received a Neutral rating from UBS. Its net sales are primarily driven by primary care products (52.3%), followed by specialty care (25.6%) and oncology (19.9%). Geographically, sales are distributed with 42.3% in the U.S., 21.9% in Europe, and 33.8% in other regions.
U.S. stocks fell on Tuesday, with the Dow experiencing its longest losing streak since February 1978, dropping for the ninth consecutive session. Investors are cautious ahead of the Federal Reserve's policy announcement, anticipating a 25 basis point rate cut, while economic data shows solid consumer spending. The S&P 500 and Nasdaq also declined, though Tesla's stock rose significantly after a price target increase.
Pfizer Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
bio protocol launches on binance launchpool for token farming opportunities
14:44 24.12.2024
emerging therapies and market dynamics for acute bacterial skin infections
Merck & Co., Inc.
Wockhardt Limited
Pfizer Inc.
Glenmark Pharmaceuticals Limited
Allergan plc
Novartis AG
JPN
FRA
GBR
ESP
USA
DEU
ITA
Gaurav Bora
Show more
19:35 23.12.2024
neostigmine methylsulfate injection market growth driven by chronic conditions and surgeries
United States Dollar
Fresenius Kabi AG
SUN Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Pfizer Inc.
Bausch Health Companies Inc.
Endo International Ltd.
Baxter International Inc.
FRA
KOR
GBR
ESP
USA
DEU
ITA
CAN
CHN
IND
BRA
ARG
ZAF
JPN
MEX
Mylan Nv
Show more
08:28 23.12.2024
two healthcare dividend stocks to consider during market volatility
12:50 22.12.2024
navigating a pricey stock market strategies for 2025 investment success
11:06 21.12.2024
global uveitis treatment market poised for significant growth by 2032
Pfizer Inc.
Bayer AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
CIPLA LTD
Lupin Limited
Hoffmann-La Roche AG
Bausch Health Companies Inc.
BIOGEN
ABBVIE
Alimera Sciences Inc.
SAU
ISR
FRA
RUS
DEU
TWN
ARG
ARE
AUT
TUR
SGP
NZL
CHL
USA
BRA
CAN
ITA
JPN
IDN
GBR
ESP
IND
MYS
COL
AUS
THA
EGY
VNM
KOR
PHL
CHN
ZAF
MEX
Nidhi Bhavsar
Show more
20:41 19.12.2024
China's ensartinib gains FDA approval for lung cancer treatment
United States Dollar
Chinese Yuan
Swiss Franc
Japanese Yen
AstraZeneca PLC
Hoffmann-La Roche AG
Pfizer Inc.
Novartis AG
CHN
USA
JPN
Show more
16:20 19.12.2024
UBS maintains neutral rating on Pfizer amid lung cancer study concerns
08:26 19.12.2024
pfizer receives neutral rating from ubs amid diverse product portfolio
08:13 19.12.2024
stocks decline as dow experiences longest losing streak since 1978
United States Dollar
Tesla, Inc.
Pfizer Inc.
USA
Jerome Powell
Richard Chang
Jason Ware
Lisa Pauline Mattackal
Brendan Mcdermid
Purvi Agarwal
Show more
22:24 17.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Global Trade Developments
Startups & Entrepreneurship
Government Economic Policies
Supply Chain Management
Retail and Consumer Goods
Industry Mergers & Acquisitions
Stock Market Updates
Venture Capital Investments
Finance Mergers & Acquisitions
Global Financial Events
Energy Sector Developments
Emerging Startups
Funding Rounds & Investments
Central Bank Actions
Fintech Startups
Cryptocurrency & Blockchain Regulations
Financial Scams and Security
Market Analysis and Predictions
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Learning Resources Inc.
MGA Entertainment Inc.
Toyota Motor Corp
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
Dell Technologies Inc.
Taiwan Semiconductor Manufacturing Company Limited
Verizon Communications Inc.
Google Inc.
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Daiwa Institute OF Research Ltd.
Pegatron Corporation
KODEX India Tata Group
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
United Arab Emirates Dirham
Australian Dollar
New Taiwan Dollar
British Pound Sterling
Vietnamese Đồng
New Zealand Dollar
South Korean Won
Thai Baht
Saudi Riyal
Indonesian Rupiah
South African Rand
Malaysian Ringgit
Singapore Dollar
Egyptian Pound
People: